Intravenous Diclofenac Administration
Administer intravenous diclofenac 37.5 mg as a bolus injection over 5-15 seconds every 6 hours for acute pain management, with a maximum daily dose of 150 mg and treatment duration not exceeding 2 days before transitioning to oral therapy.
Dosing and Administration
Standard Dosing
- Initial dose: 18.75-37.5 mg IV bolus 1, 2, 3
- Frequency: Every 6 hours as needed 2
- Maximum daily dose: 150 mg 4
- Administration speed: 5-15 seconds for bolus injection 1
- Duration: Limit to 48 hours; transition to oral formulation if longer treatment needed 4
The newer hydroxypropyl-β-cyclodextrin (HPβCD) formulations allow for small-volume bolus administration (1 mL) rather than requiring dilution and prolonged infusion 1, 2. These formulations achieve peak plasma concentrations in approximately 3 minutes (0.05 hours), providing rapid onset of analgesia 1.
Dose Selection
For moderate-to-severe acute pain: Start with 37.5 mg IV bolus. Both 18.75 mg and 37.5 mg demonstrate significant efficacy versus placebo, with the higher dose showing marginally better pain relief (66% vs 57% achieving ≥50% pain reduction) 5. The number needed to treat (NNT) for 50% pain relief is 2.4 at 4 hours and 3.8 at 6 hours versus placebo 5.
Alternative Formulations
Traditional formulations (75 mg/3 mL) require dilution and 30-minute infusion 1. For intramuscular administration in primary care settings: 75 mg IM is recommended for acute renal colic when IV access is impractical 6.
Contraindications
Absolute Contraindications (FDA Label)
- Pregnancy ≥30 weeks gestation: Risk of premature ductus arteriosus closure 4
- Active peptic ulcer disease or gastrointestinal bleeding 4
- History of asthma, urticaria, or allergic reactions to NSAIDs or aspirin 4
- Coronary artery bypass graft (CABG) surgery perioperative period 4
- Heart failure (NYHA Class III-IV) 4
- Severe renal impairment (CrCl <30 mL/min) 4
- Severe hepatic impairment 4
Relative Contraindications Requiring Caution
- Pregnancy 20-30 weeks: Use lowest effective dose for shortest duration; monitor for oligohydramnios if treatment exceeds 48 hours 4
- Age >60 years: Increased cardiovascular and gastrointestinal bleeding risk; consider alternative analgesics 6, 4
- Cardiovascular disease or risk factors: Diclofenac carries cardiovascular risks at all doses, including low doses 7
- Concurrent anticoagulation or antiplatelet therapy 4
- History of gastrointestinal disease 6
Monitoring Requirements
Immediate Monitoring (During Administration)
- Injection site assessment: High risk of venous thrombosis with undiluted formulations (85% in hand veins, 58% in antecubital veins with 25 mg/mL concentration) 8
- Vital signs: Blood pressure, heart rate to detect cardiovascular events 4
- Allergic reactions: Monitor for 30 minutes post-injection 4
Short-Term Monitoring (During Treatment Course)
- Pain assessment: Evaluate response within 30-60 minutes; failure to respond warrants alternative management 6
- Renal function: Particularly in elderly, volume-depleted, or those with pre-existing renal impairment 4
- Gastrointestinal symptoms: Abdominal pain, melena, hematemesis 4
High-Risk Populations Requiring Enhanced Monitoring
- Elderly patients (>65 years): Monitor renal function, blood pressure, and gastrointestinal symptoms closely 4
- Patients with cardiovascular risk factors: Both high-dose (≥150 mg/day) and low-dose (<150 mg/day) diclofenac increase cardiovascular event rates comparably (IRR 1.55 vs 1.52) 7
- Pregnancy (if unavoidable use at 20-30 weeks): Ultrasound monitoring for oligohydramnios if treatment exceeds 48 hours 4
Clinical Pearls and Pitfalls
Formulation-Specific Considerations
Avoid undiluted traditional formulations for IV bolus: The 25 mg/mL concentration causes unacceptably high thrombophlebitis rates (85% in hand veins). If using traditional formulations, dilute to 5 mg/mL in normal saline to reduce thrombosis risk to 38% in hand veins and 8% in antecubital veins 8.
Cardiovascular Risk
Do not assume low-dose diclofenac is cardiovascular-safe: Recent evidence demonstrates comparable cardiovascular risk between high-dose (≥150 mg/day) and low-dose (<150 mg/day) diclofenac, with approximately 50% increased rate of major adverse cardiovascular events versus non-users 7. This risk appears within 30 days of initiation.
Opioid-Sparing Effect
IV diclofenac significantly reduces opioid requirements: median time to rescue morphine increases from 80 minutes (placebo) to 226 minutes (diclofenac), with NNT to prevent rescue medication use of 3.0 5. This opioid-sparing effect reduces opioid-related adverse events.
Duration Limitation
Limit IV diclofenac to acute settings (≤48 hours): Transition to oral formulation or discontinue based on clinical response 4. Prolonged parenteral NSAID use increases adverse event risk without additional benefit.
Special Populations to Avoid
- Patients with chronic headache: Paradoxically high cardiovascular risk (IRR 5.10) 7
- Post-CABG surgery patients: Absolute contraindication 4
- Late pregnancy (≥30 weeks): Absolute contraindication 4
Efficacy Expectations
Patients should experience meaningful pain relief within 30-60 minutes of administration 6. The proportion achieving ≥50% pain relief is approximately 60-70% with standard dosing 5. If adequate analgesia is not achieved within 1 hour, consider alternative analgesics or hospital admission for further evaluation 6.